BioMarin Pharmaceutical (BMRN)
Healthcare · Biotechnology
1 member of Congress has disclosed 1 trade in BioMarin Pharmaceutical (BMRN) since 2023: 0 buys and 1 sale. The most recent was disclosed on Apr 17, 2023.
- Trades disclosed
- 1
- Members trading
- 1
- Buys / sells
- 0 / 1
- Reported value
- $1K–$15K
Keep following the company.
Subscribers get new congressional filings and notable insider purchases for companies they follow. Coverage varies by company.
What else is happening at BMRN
All research →Company filings and public records connected to this stock, ordered by when they became public or were first observed.
BMRN: third_quarter 2026 lobbying report
H.R.10571: SURGE TO SAVE NEWBORNS ACT; PROVISIONS RELATED TO NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING UTILIZATION MANAGEMENT GENERAL DISCUSSIONS REGARDING TARIFFS H.R.10359: PRIORITY FOR PEDIATRIC CURES ACT; PROVISIONS RELATED TO REMOVAL OF RARE PEDIATRIC PRIORITY REVIEW VOUCHERS SUNSET GENERAL DISCUSSIONS REGARDING CLINICAL TRIALS H.R. 1414: CAMERON'S LAW; ALL PROVISIONS DISCUSSIONS REGARDING INTELLECTU
Public: Oct 20, 2026, 4:44 PM EDTOriginal source ↗BMRN: third_quarter 2026 lobbying report
Provide strategic counsel and advocacy on issues relating to biopharmaceuticals for rare diseases driven by genetic causes generally, or BioMarin Pharmaceutical specifically.
Public: Oct 20, 2026, 1:22 PM EDTOriginal source ↗BMRN: second_quarter 2026 lobbying report
GENERAL DISCUSSIONS REGARDING MEDICAID GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING PATIENT EXPERIENCE DATA GENERAL DISCUSSIONS REGARDING RECOMMENDED UNIFORM SCREENING PANEL (RUSP) CONDITION ADDITION GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION GENERAL DISCUSSIONS REGARDING UTILIZATION MANAGEMENT GENERAL DISCUSSIONS REGARDING TARDE GENERAL DISCUSSIONS REGARDING CLI
Public: Jul 20, 2026, 5:14 PM EDTOriginal source ↗BMRN: second_quarter 2026 lobbying report
GENERAL DISCUSSIONS REGARDING MEDICAID GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING PATIENT EXPERIENCE DATA GENERAL DISCUSSIONS REGARDING RECOMMENDED UNIFORM SCREENING PANEL (RUSP) CONDITION ADDITION GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION GENERAL DISCUSSIONS REGARDING UTILIZATION MANAGEMENT GENERAL DISCUSSIONS REGARDING TARDE GENERAL DISCUSSIONS REGARDING CLI
Public: Jul 20, 2026, 5:06 PM EDTOriginal source ↗BMRN: second_quarter 2026 lobbying report
GENERAL DISCUSSIONS REGARDING MEDICAID GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING PATIENT EXPERIENCE DATA GENERAL DISCUSSIONS REGARDING RECOMMENDED UNIFORM SCREENING PANEL (RUSP) CONDITION ADDITION GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION GENERAL DISCUSSIONS REGARDING UTILIZATION MANAGEMENT GENERAL DISCUSSIONS REGARDING TARDE GENERAL DISCUSSIONS REGARDING CLI
Public: Jul 20, 2026, 4:24 PM EDTOriginal source ↗
Who traded BMRN
- Rep. Daniel S. Goldman (D-NY-10)0 buys · 1 sale01Apr 17, 2023
All trades
- Apr 17, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
Sold BioMarin Pharmaceutical BMRN
$1K–$15K · Traded Mar 6, 2023 · disclosed Apr 17, 2023
From periodic transaction reports filed under the STOCK Act. Amounts are the ranges members report, and trades can be disclosed up to 45 days after they happen. Nothing here is investment advice.